The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: A comprehensive analysis.
Peng HuangYan WangMing YueZhijun GeXueshan XiaAndre J JeyarajanJacinta A HolmesRongbin YuChuanwu ZhuSheng YangWenyu LinRaymond T ChungPublished in: Liver international : official journal of the International Association for the Study of the Liver (2021)
The HCV recurrence risk after achieving SVR with all-oral DAAs therapy is low, and the risk of HCV recurrence in high-risk and HIV/HCV-coinfected populations was driven by an increase in reinfection rather than late relapse.